Montironi R, Cheng L, Mazzucchelli R, Santinelli A, Bono A, Lopez-Beltran A
Urologia. 2008 Jul-Sep;75(3):149-55.
A variety of putative prostate cancer markers have been described in human serum, urine, seminal fluid, and histological specimens. These markers exhibit varying capacities to detect prostate cancer and to predict disease course. In order to be considered markers for diagnosis or prognosis of disease course, and to be brought forward for large-scale clinical evaluation, they should fulfill several criteria. Firstly, there should be a biological or therapeutic rationale for choosing the marker, or at least a consistent association with disease presence, disease characteristics such as stage, or disease aggressiveness. Secondly, there should be an assessment of the strength of marker association with disease outcome. Thirdly, the marker should be assessed as an independent predictor in a multivariate analysis.
在人血清、尿液、精液和组织学标本中已描述了多种假定的前列腺癌标志物。这些标志物在检测前列腺癌和预测疾病进程方面表现出不同的能力。为了被视为疾病进程诊断或预后的标志物,并被提出来进行大规模临床评估,它们应满足几个标准。首先,选择该标志物应有生物学或治疗学依据,或者至少与疾病存在、疾病特征(如分期)或疾病侵袭性有一致的关联。其次,应该评估标志物与疾病结果关联的强度。第三,在多变量分析中,该标志物应被评估为独立预测因子。